Compositions Of Human Prothrombin And Activated Factor X For Improving Hemostasis In The Treatment Of Bleeding Disorders

Patent No. EP3116534 (titled "Compositions Of Human Prothrombin And Activated Factor X For Improving Hemostasis In The Treatment Of Bleeding Disorders") was filed by Baxalta on Mar 13, 2015. The application was issued on May 29, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
OCTAPHARMAFeb 28, 2020ULLRICH & NAUMANN PARTG MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3116534

BAXALTA
Application Number
EP15712018A
Filing Date
Mar 13, 2015
Status
Revoked
Nov 6, 2020
Publication Date
May 29, 2019